2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
779
Lung Neoplasms
345
Ovarian Neoplasms
323
Breast Neoplasms
279
Fallopian Tube Neoplasms
159
Triple Negative Breast Neoplasms
145
Small Cell Lung Carcinoma
144
Neoplasms
137
Squamous Cell Carcinoma of Head and Neck
123
Carcinoma, Ovarian Epithelial
114
Neoplasm Metastasis
85
Head and Neck Neoplasms
80
Endometrial Neoplasms
76
Uterine Cervical Neoplasms
72
Esophageal Neoplasms
71
Adenocarcinoma of Lung
70
Neuroblastoma
55
Central Nervous System Neoplasms
53
Lymphoma, Large B-Cell, Diffuse
49
Carcinoma
49
Recurrence
48
Brain Neoplasms
48
Prostatic Neoplasms
44
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Urinary Bladder Neoplasms
42
Esophageal Squamous Cell Carcinoma
41
Lymphoma
39
Melanoma
35
Carcinoma, Squamous Cell
33
Stomach Neoplasms
31
Interventions
pembrolizumab
3
Pemetrexed
2
Cholecalciferol
2
vorasidenib
1
relacorilant
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
bosutinib
1
Trastuzumab
1
Sunitinib
1
Morphine
1
Methadone
1
MRX-2843
1
Letrozole
1
Imatinib Mesylate
1
Electrochemotherapy
1
Control Groups
1
Clomiphene
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Bevacizumab
1
Azacitidine
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Carboplatin
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled